Form 144 MEIRAGTX HOLDINGS PLC For: 17 November By Investing.com
Investing.com reported on a Form 144 filing for MEIRAGTX HOLDINGS PLC related to November 17. The article notes the company's stock symbol MGTX and its current performance with a -1.74% change. This filing indicates an intent to sell restricted or controlled securities by an affiliate.
Form 4 MeiraGTx Holdings PLC: Alexandria Forbes (Director, PRESIDENT & CEO) For: 17 November By Investing.com
This article reports on a Form 4 filing for MeiraGTx Holdings PLC, detailing insider transactions by Alexandria Forbes, who serves as a Director, President, and CEO. The filing is specifically for November 17th. The article is a brief announcement of this financial disclosure.
Form 144 MEIRAGTX HOLDINGS PLC For: 17 November By Investing.com
This article announces the filing of Form 144 for MEIRAGTX HOLDINGS PLC on November 17. Form 144 is a notice of the intent to sell restricted securities, typically filed with the SEC. The brief entry provides no further details beyond the company name and filing date.
Form 4 MeiraGTx Holdings PLC: Alexandria Forbes (Director, PRESIDENT & CEO) For: 17 November
This article reports on a Form 4 filing for MeiraGTx Holdings PLC, detailing an insider transaction by Alexandria Forbes, who serves as a Director, President, and CEO. The filing pertains to activity on November 17, indicating a disclosure of changes in beneficial ownership. The article provides the core information of the regulatory filing without further details on the transaction itself.
The CEO of MeiraGTx (MGTX) sold 62,000 shares and gave away another 24,100 on Nov. 17.
MeiraGTx Holdings plc (MGTX) President & CEO Alexandria Forbes sold 62,000 ordinary shares for approximately $524,000 at a weighted-average price of $8.45 per share on November 17, 2026. This transaction was executed under a Rule 10b5-1 trading plan. Additionally, Forbes gifted 24,100 ordinary shares on the same day.
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
MeiraGTx Holdings plc announced an oral presentation at ObesityWeek 2026 in Washington, DC, highlighting its AAV-BDNF program for severe early-onset obesity. The presentation, delivered by Josefa Sullivan, detailed how hypothalamic AAV-BDNF restores the leptin-melanocortin pathway, rescuing metabolic and neurobehavioral phenotypes in obesity models. This genetic medicine aims to address both life-threatening obesity and debilitating neurobehavioral symptoms associated with BDNF haploinsufficiency.
Form S-3ASR MeiraGTx Holdings PLC For: 14 November By Investing.com
This article announces that MeiraGTx Holdings PLC filed a Form S-3ASR with the SEC on November 14th. The filing is a standard procedure for certain types of securities offerings, indicating the company's potential intent to raise capital in the future. The stock symbol MGTX is noted with a 4.44% increase in this article.
Form S-3ASR MeiraGTx Holdings PLC For: 14 November By Investing.com
Investing.com reports on the filing of Form S-3ASR by MeiraGTx Holdings PLC for November 14. The article primarily consists of this brief announcement along with various financial market data, indices, and popular news articles from Investing.com. It highlights MeiraGTx Holdings PLC (MGTX) with a stock change of +4.44%.
Form S-3ASR MeiraGTx Holdings PLC For: 14 November By Investing.com
This article reports on the filing of Form S-3ASR by MeiraGTx Holdings PLC on November 14, 2026. The content provides the filing information and references the company's stock symbol MGTX. The article offers no further details or analysis beyond the filing announcement.
MeiraGTx Holdings plc (MGTX) News, Articles, Events & Latest Updates
This article provides recent news and updates for MeiraGTx Holdings plc (MGTX), including its Q3 2026 earnings report where it missed revenue estimates. It also highlights the company's Q2 2026 performance where both earnings and revenues surpassed estimates. Additionally, the page features news for other companies like Alpha Cognition, Orchestra BioMed, Graviton BioScience, TScan Therapeutics, Voyager Therapeutics, Pacira, and uniQure, primarily focusing on their quarterly earnings reports and some trial results or IND clearances.
MeiraGTx Holdings plc (MGTX) Misses Q3 EPS by 3c
MeiraGTx Holdings plc (MGTX) reported a Q3 EPS of ($0.53), missing the analyst estimate by $0.03. The company's revenue for the quarter was $4.81 million, which was below the consensus estimate of $7.07 million.
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) reported a Q3 loss of $0.53 per share, missing the Zacks Consensus Estimate of a $0.46 loss, though this was an improvement from a $0.62 loss a year ago. The company also missed revenue estimates, posting $4.81 million against an expected $6.87 million. Despite these misses, MGTX shares have gained 21.8% year-to-date, outperforming the S&P 500.
MeiraGTx Reports $4.8 Million Q3 Revenue and $51.3 Million Net Loss
MeiraGTx Holdings plc reported third-quarter 2026 revenue of $4.8 million and a net loss of $51.3 million. The company expects to submit a marketing authorization application for bota-vec in December 2026 and a U.S. biologics license application in Q1 2027. Insider trading activity showed sales by executives, while institutional investors had mixed activity, with some adding and others decreasing their positions.
MGTX: MeiraGTx Holdings plc filed SEC Form 8-K: Results of...
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K detailing its Q3 2026 results, reporting a net loss of $51.3 million and cash and equivalents of $184.7 million. The company expects to fund operations into the second half of 2028 with current cash and an anticipated $95.0 million payment from Hologen. MeiraGTx also plans to submit a Marketing Authorisation Application to the EMA for bota-vec in December 2026 and a Biologics License Application to the FDA in Q1 2027.
MGTX: MeiraGTx Holdings plc filed SEC Form 8-K: Results of...
MeiraGTx Holdings plc reported its Q3 2026 financial results, including a net loss of $51.3 million and cash and equivalents of $184.7 million. The company expects to submit a Marketing Authorisation Application for bota-vec to the EMA in December 2026 and believes its current capital, plus an expected Hologen payment, will fund operations into the second half of 2028.
MeiraGTx Holdings PLC (328.MU) Seasonal returns chart
This article provides a seasonal returns chart for MeiraGTx Holdings PLC (328.MU), showing the average monthly price return between 2020 and 2026. The stock is currently trading at 8.60 EUR, up 4.24%, as of 8:02:45 CET. The chart helps investors understand historical seasonal trends for the company's stock performance.
MeiraGTx Holdings PLC (328.MU) Seasonal returns chart
This article presents a seasonal returns chart for MeiraGTx Holdings PLC (328.MU), displaying the average monthly price return from 2020 to 2026. The stock closed at 8.45 EUR, showing no change at the close on November 5. The data is provided by Yahoo Finance.
MeiraGTx Holdings PLC (328.MU) Seasonal returns chart - Yahoo Finance
This Yahoo Finance article displays the seasonal returns chart for MeiraGTx Holdings PLC (328.MU), indicating its average monthly price return from 2020 to 2026. The stock was last quoted at 8.45 EUR, showing no change. The data includes options for viewing 3-year, 5-year, 10-year, 20-year, and all-time seasonality.
MeiraGTx Holdings plc (MGTX) Seasonal returns chart - Yahoo Finance
The article displays the seasonal returns chart for MeiraGTx Holdings plc (MGTX) on Yahoo Finance. It shows the average monthly price return for the company from 2018 to 2026. The stock was trading at 9.42 USD at market close on November 4th.
MeiraGTx Holdings PLC (328.MU) stock price, news, quote and history
This page provides detailed financial information for MeiraGTx Holdings PLC (328.MU), including its current stock price, historical data, and performance overview. It shows a stock price of 8.45 EUR with no change at market close on November 4th and tracks its returns against the S&P 500 benchmark over various periods. The article also includes key valuation measures, profitability metrics, and balance sheet highlights.
MeiraGTx Holdings plc (MGTX) Seasonal returns chart
This article provides a seasonal returns chart for MeiraGTx Holdings plc (MGTX), showing the average monthly price return from 2018 to 2026. As of October 30th, MGTX's stock price was $9.49, having decreased by 2.22%. The page also includes general market data for various indices and currencies.
MeiraGTx stock: New gene-therapy data span eye, ALS and xerostomia
MeiraGTx (MGTX) stock is in focus after new gene-therapy research spanning ALS, retinal disease, and xerostomia. The company presented preclinical or development-stage data at major scientific congresses, including a potency assay for xerostomia, findings on oxidative stress in dry age-related macular degeneration, and preclinical work for ALS. MeiraGTx also highlighted a new analytical method for AAV capsid proteins, important for quality control in manufacturing.
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MeiraGTx Holdings plc announced it will present four posters at two upcoming scientific meetings: the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting, both running from October 27-30, 2026. The presentations will highlight the company's progress in genetic medicine and cell therapy platforms, covering topics such as a potency assay for xerostomia treatment, characterization of AAV vectors, AAV-NRF2 for dry AMD, and AAV-mediated gene medicine for ALS. These studies demonstrate MeiraGTx's therapeutic potential across various inherited and common diseases.
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MeiraGTx Holdings plc announced it will present four posters at two upcoming scientific conferences: three at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and one at the Network of Excellence for ALS (NEALS) Annual Meeting, both held from October 27-30, 2026. The presentations highlight the company's advancements in genetic medicine and cell therapy, including a potency assay for Xerostomia treatment, a method for AAV characterization, an AAV-NRF2 therapy for dry AMD, and AAV-mediated gene medicine for ALS. These studies showcase MeiraGTx's broad pipeline and its commitment to developing novel therapeutic options for various diseases.
Understanding Momentum Shifts in (MGTX)
Meiragtx Holdings Plc (NASDAQ: MGTX) is showing weak near and mid-term sentiment which could challenge its long-term positive outlook, with elevated downside risk. AI models have generated three distinct trading strategies for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The multi-timeframe signal analysis indicates weak sentiment in the near and mid-term, but strong sentiment for the long-term.
MeiraGTx Holdings plc Estimates – NASDAQ:MGTX
This page on TradingView provides financial data and analyst estimates for MeiraGTx Holdings plc (NASDAQ: MGTX). Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time across income statements, balance sheets, cash flow statements, and valuation metrics. The platform emphasizes the importance of independent research and disclaims that the information is not investment advice.
Form 144 MEIRAGTX HOLDINGS PLC For: 20 October By Investing.com
This article announces the filing of Form 144 for MEIRAGTX HOLDINGS PLC on October 20th. The document, published by Investing.com, likely details insider transactions or intentions to sell restricted securities. The article provides minimal information beyond the filing announcement.
Form 144 MEIRAGTX HOLDINGS PLC For: 20 October By Investing.com
This article reports on the filing of Form 144 by MEIRAGTX HOLDINGS PLC for October 20. It includes the stock symbol MGTX and was published by Investing.com. The content primarily announces this financial filing without providing further details about its implications.
Form 4 MeiraGTx Holdings PLC: Richard Giroux (CFO & COO) For: 20 October
This article reports on a Form 4 filing for MeiraGTx Holdings PLC, detailing insider transactions by Richard Giroux, the CFO & COO, on October 20. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders, providing transparency to investors.
Form 144 MEIRAGTX HOLDINGS PLC For: 20 October By Investing.com
This article announces the filing of Form 144 by MEIRAGTX HOLDINGS PLC for October 20. Form 144 is a notice of the intent to sell restricted securities in compliance with SEC Rule 144. The brief piece serves as a notification of this financial activity.
Form 4 MeiraGTx Holdings PLC: Richard Giroux (CFO & COO) For: 20 October By Investing.com
This article reports on a Form 4 filing for MeiraGTx Holdings PLC, detailing insider transactions by Richard Giroux, CFO & COO, for October 20. The brief notice from Investing.com indicates that the filing is available for public review.
Form 4 MeiraGTx Holdings PLC: Richard Giroux (CFO & COO) For: 20 October
This article reports on a Form 4 filing for MeiraGTx Holdings PLC, detailing that Richard Giroux, the CFO and COO, made a filing for October 20th. The report was published on October 21, 2026, at 02:20. The stock symbol MGTX is mentioned, showing a 2.15% increase.
Under a trading plan, MeiraGTx (MGTX) CFO sells 56,000 shares at a $9.95 average price.
MeiraGTx Holdings plc's CFO and COO, Richard Giroux, sold 56,000 ordinary shares on October 20, 2026, at a weighted average price of $9.95 per share. These sales were conducted under a Rule 10b5-1 trading plan established on November 18, 2025. Following the transaction, Giroux's direct holdings amount to 852,530 ordinary shares, with additional indirect holdings through his spouse and Aigle Healthcare Partners III LLC.
MeiraGTx CFO & COO Richard Giroux sells $557,200 in company shares
Richard Giroux, CFO and COO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 56,000 ordinary shares for $557,200 on October 20, 2026, through a Rule 10b5-1 trading plan. Despite recent stock weakness, MGTX shares are up 25% year-to-date and are considered undervalued by InvestingPro analysis. The sale comes amidst differing analyst ratings and ongoing developments in MeiraGTx's gene therapy programs, including the reacquisition of rights to bota-vec.
Form 144 MEIRAGTX HOLDINGS PLC For: 20 October By Investing.com
Investing.com reported on a Form 144 filing for MEIRAGTX HOLDINGS PLC pertaining to October 20. The article is a brief financial news item indicating that the company filed this form, relevant for certain restricted securities transactions. It notes a 5.50% increase in MGTX stock.
MeiraGTx CFO Richard Giroux Executes Sale of 56,000 Shares Under Rule 10b5-1 Plan
Richard Giroux, CFO and COO of MeiraGTx Holdings plc (NASDAQ: MGTX), sold 56,000 ordinary shares on October 20, 2026. This sale was executed under a pre-established Rule 10b5-1 trading plan at a weighted average price of $9.95 per share. Following the transaction, Giroux's direct ownership in the company stands at 852,530 ordinary shares.
Form 144 MeiraGTx Holdings plc Filed by: Giroux Richard
Richard Giroux, an officer of MeiraGTx Holdings plc, has filed a Form 144 with the SEC, indicating his intent to sell 56,000 ordinary shares of the company. These shares, with an aggregate market value of $557,200, were acquired through incentive compensation stock grants in 2018. Giroux has also sold 56,000 ordinary shares in the past three months, generating gross proceeds of $700,560.
Nine analysts set USD 24.71 target for MeiraGTx stock
Nine analysts have set an average 12-month target of USD 24.71 for MeiraGTx Holdings plc, maintaining a Moderate Buy consensus. The company reported strong second-quarter revenues of USD 321.43 million, significantly beating the consensus, and is expected to release its third-quarter results on November 12, 2026. MeiraGTx, a clinical-stage genetic medicines company, has a market capitalization of USD 971.0 million.
Nine analysts set USD 24.71 target for MeiraGTx stock
Nine analysts have set an average 12-month target of USD 24.71 for MeiraGTx (MGTX), representing a 166.27% increase from its current Nasdaq price of USD 9.28 as of October 16, 2026. The company reported strong second-quarter 2026 revenues of USD 321.43 million, significantly exceeding expectations, with adjusted earnings per share of USD 1.71. Investors are now looking to the third-quarter results, expected on November 12, 2026, to assess the repeatability of this performance.
MeiraGTx stock rises to EUR 8.78, volume 39.05 percent below average
MeiraGTx stock increased by 4.36 percent on Nasdaq to EUR 8.78, though trading volume was 39.05 percent below its average. The company, a clinical-stage biotechnology firm, has a market capitalization of USD 943.1 million and analysts give it a "Moderate Buy" consensus with an average target of USD 24.71. MeiraGTx focuses on genetic medicines for conditions like Parkinson's disease and inherited retinal disease.
Form 144 MeiraGTx Holdings plc For: 11 October By Investing.com
This article from Investing.com reports on the filing of Form 144 by MeiraGTx Holdings plc on October 11. It's a very brief news item, noting the company's stock symbol MGTX and its current performance. The content primarily serves as a placeholder for the Form 144 announcement.
Form 144 MeiraGTx Holdings plc For: 11 October By Investing.com
This article reports on the filing of Form 144 by MeiraGTx Holdings plc for October 11, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and mentions the stock symbol MGTX.
Form 144 MeiraGTx Holdings plc For: 11 October By Investing.com
This article reports on the filing of Form 144 by MeiraGTx Holdings plc for October 11, 2026. The brief announcement, published by Investing.com, indicates a routine regulatory disclosure related to proposed sales of restricted securities. The article includes relevant stock market data for MeiraGTx Holdings plc (MGTX) and other market indices and commodities.
Form 4 MeiraGTx Holdings PLC For: 11 October By Investing.com
This article announces the filing of Form 4 for MeiraGTx Holdings PLC on October 11, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders whenever they trade shares in their own company. The article provides no further details beyond the filing announcement.
Form 4 MeiraGTx Holdings PLC For: 11 October By Investing.com
This article reports on the filing of Form 4 for MeiraGTx Holdings PLC, which occurred on October 11, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article indicates this is a financial market news item.
MeiraGTx chief scientific officer Naylor sells $294,291 in shares
MeiraGTx's Chief Scientific Officer of Ophthalmology, Stuart Naylor, sold 27,659 ordinary shares totaling $294,291 on October 6, 2026, pursuant to a pre-adopted trading plan. Following the transactions, Naylor beneficially owns 613,187 shares. The company's stock is trading near its Fair Value, and despite recent analyst activity showing mixed perspectives on its gene therapies, MeiraGTx remains profitable.
Form 4 MeiraGTx Holdings PLC For: 6 October By Investing.com
This article from Investing.com is a standard financial report titled "Form 4 MeiraGTx Holdings PLC For: 6 October". It provides information about MeiraGTx Holdings PLC and typically contains details about insider transactions or changes in beneficial ownership. The article is very brief and does not contain extensive body text beyond the title.
Form 4 MeiraGTx Holdings PLC For: 6 October By Investing.com
The article is a Form 4 filing for MeiraGTx Holdings PLC, detailing activity on October 6. It appears to be a standard regulatory filing notification published by Investing.com, accompanied by various market data and other news headlines.
MeiraGTx Holdings PLC (MGTX) Insider Stuart Naylor Sells 27,659 Shares
Stuart Naylor, Chief Scientific Officer at MeiraGTx Holdings PLC (MGTX), sold 27,659 shares on October 6, 2026, contributing to a year-long pattern of insider selling with no corresponding buys. The stock is trading at $10.64, significantly below its GF Value of $80.69, placing it in the "Possible Value Trap, Think Twice" category. This consistent insider distribution and the valuation signal suggest caution for investors, highlighting inherent risks in clinical-stage biotechnology.
Form 4 MeiraGTx Holdings PLC For: 6 October By Investing.com
This article reports on the filing of Form 4 for MeiraGTx Holdings PLC, specifically covering transactions that occurred on October 6th. Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article itself is very brief, mainly serving as an announcement of the filing.